

Germany's Bayer to buy US gene therapy specialist AskBio

October 26 2020

German health care company Bayer said Monday it is buying Asklepios BioPharmaceutical, a U.S.-based firm specializing in gene therapy, in a deal worth up to \$4 billion.

Bayer said it will pay \$2 billion up front for privately held AskBio plus "potential success-based milestone payments" of up to another \$2 billion. About three-quarters of the latter are expected to be due over the next five years, it added.

AskBio is headquartered at Research Triangle Park, North Carolina, and has facilities in Edinburgh, Paris and San Sebastián, Spain.

The acquisition will allow Bayer to advance "the establishment of a cell and gene therapy platform that can be at the forefront of breakthrough science, contributing to preventing or even curing diseases caused by [gene defects](#) and further driving company growth in the future," Bayer CEO Werner Baumann said.

Bayer said it will own full rights to AskBio's [gene therapy](#) platform, but AskBio "will continue to operate as an independent company on an arm's-length basis."

Regulatory approval is required for the transaction, which is expected to close during the current quarter.

© 2020 The Associated Press. All rights reserved. This material may not

be published, broadcast, rewritten or redistributed without permission.

Citation: Germany's Bayer to buy US gene therapy specialist AskBio (2020, October 26)
retrieved 25 April 2024 from

<https://medicalxpress.com/news/2020-10-germany-bayer-gene-therapy-specialist.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.